RESUMO
PURPOSE: The purpose of this study was to evaluate the use of indocyanine green-guided nonpalpable breast cancer lesion localization (INBCL) and to compare it with ultrasound localization (US). METHODS: We retrospectively reviewed 78 consecutive patients undergoing breast-conserving surgery for nonpalpable breast cancer (NBC). Of all 78 excisions, 42 cases were guided by INBCL and 36 by US. RESULTS: The rate of clear margins was 90.5% (38/42) in the INBCL group compared to the 83.3% (30/36) in the US (P = .548). A comparison of the margins at first excision for both INBCL and US, in the INBCL series, 92.9% (39/42) of cases had a margin less than 5 mm, whereas for US series, it was 72.2% (26/36) (P = .033). When results of the excised tissue are taken into account, the mean specimen volume for INBCL was 58 cm3, but for US it was 73 cm3, with difference in mean volume being 15 cm3 (P = .062). CONCLUSIONS: INBCL for NBCs was more accurate than US because a smaller volume of the tissue may be excised by using the technique, without compromising margin status in nonpalpable lesions.
Assuntos
Neoplasias da Mama , Mastectomia Segmentar , Feminino , Humanos , Mastectomia Segmentar/métodos , Verde de Indocianina , Neoplasias da Mama/diagnóstico por imagem , Neoplasias da Mama/cirurgia , Neoplasias da Mama/patologia , Ultrassonografia Mamária/métodos , Estudos Retrospectivos , Margens de Excisão , Ultrassonografia de IntervençãoRESUMO
Male accessory breast cancer is an extremely rare tumor. There is no report about its monotherapy and subsequent outcome prior to 2022. The current study presents the case of a 76-year-old male patient with a hard mass in the left axilla. Histopathologic examination of an excisional specimen indicated an adenocarcinoma compatible with breast carcinoma. Immunohistochemical analysis demonstrated that the mass was estrogen receptor (ER) (-), progesterone receptor (PR)(-), and human epidermal growth factor receptor type 2 (HER2) (-). A diagnosis of breast cancer originating from the accessory mammary gland in the axilla was made. Two years following surgery, the patient presented with a pulmonary lesion. Core needle biopsy was performed, and the lesion was found to be ER (-), PR(-), and HER2 (3+). The patient was successfully treated with single-agent trastuzumab. Single-agent trastuzumab could be a reasonable regimen for metastatic accessory breast cancer patients with HER2 overexpression for whom chemotherapy and endocrine therapy are not suitable.